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Elizabeth E Roughead1, Lisa M Kalisch Ellett1*, Emmae N Ramsay2, Nicole L Pratt2, John D Barratt1,
Vanessa T LeBlanc1, Philip Ryan2, Robert Peck3, Graeme Killer3 and Andrew L Gilbert1Abstract
Background: The Australian Government Department of Veterans’ Affairs (DVA) funds an ongoing health
promotion based program to improve use of medicines and related health services, which implements
interventions that include audit and feedback in the form of patient-specific feedback generated from administrative
claims records. We aimed to determine changes in medicine use as a result of the program.
Methods: The program provides targeted patient-specific feedback to medical practitioners. The feedback is supported
with educational material developed by a clinical panel, subject to peer review and overseen by a national editorial
committee. Veterans who meet target criteria also receive educational brochures. The program is supported by a
national call centre and ongoing national consultation. Segmented regression analyses (interrupted time series)
were undertaken to assess changes in medication use in targeted veterans pre and post each intervention.
Results: 12 interventions were included; three to increase medicine use, seven which aimed to reduce use, and
two which had combination of messages to change use. All programs that aimed to increase medicine use were
effective, with relative effect sizes at the time of the intervention ranging from 1% to 8%. Mixed results were seen
with programs aiming to reduce inappropriate medicine use. Highly specific programs were effective, with relative
effect sizes at the time of the intervention of 10% decline in use of NSAIDs in high risk groups and 14% decline in
use of antipsychotics in dementia. Interventions targeting combinations of medicines, including medicine
interactions and potentially inappropriate medicines in the elderly did not change practice significantly.
Interventions with combinations of messages targeting multiple components of practice had an impact on one
component, but not all components targeted.
Conclusions: The Veterans’ MATES program showed positive practice change over time, with interventions
increasing use of appropriate medicines where under-use was evident and reduced use of inappropriate medicines
when single medicines were targeted. Combinations of messages were less effective, suggesting specific messages
focusing on single medicines are required to maximise effect. The program provides a model that could be
replicated in other settings.
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The difficulty in translating research findings to the
practice setting has been well described [1,2], particu-
larly in the area of medicines use. Under-prescribing of
effective medicines is common, as is use of too much
medicine, use of the wrong drug, and use of an inappro-
priate medicine regimen [3,4]. Bridging the evidence-
practice gap in the area of medicines-related health care
is critical because medicines are the most commonly
used health care intervention [5], and there is a significant
gap between existing evidence and practice in relation to
medicine use [6]. Implementation research provides evi-
dence to guide the design of quality improvement pro-
grams, which can promote the translation of research
findings to practice and improve the use of medicines, pa-
tient care, and health outcomes [1].
Audit and feedback are often promoted to improve
use of medicines; however, systematic reviews of inter-
ventions to improve uptake of evidence in practice have
found mixed success [1,7]. A systematic review of ran-
domized controlled trials of audit and feedback found
that some interventions were associated with a large in-
crease in adherence to practice guidelines, while others
had a negative effect [7]; the median relative percentage
practice improvement was 8 percent, with the adjusted
risk ratio varying from 0.7 to 18 across studies [7]. The
duration of effect following intervention also varied, with
improvements in practice seen in some studies at up to
six months follow-up, while in other studies there was
no difference between intervention and control groups
at three weeks post intervention [7]. Some studies found
no difference between intervention and control groups
at any point of time during follow-up [7]. Audit and
feedback interventions were more likely to have an effect
when baseline adherence to the targeted treatment
guideline was low, however, the effect was still modest
[7]. This may be because many implementation studies
do not consider communication, behavioral, and health
promotion theories in their design. One review of guide-
line implementation studies found that less than 10
percent of studies identified the theoretical rationale
underpinning the intervention [1]. While results vary,
collectively, the evidence suggests audit and feedback is
effective. From an implementation science perspective,
the next research question becomes how to implement
audit and feedback routinely as part of ongoing routine
health-care improvement.
In this paper we report the results of an ongoing
health promotion–based quality improvement program
that uses audit and feedback in the form of patient spe-
cific feedback generated from administrative claims data
to improve use of medicines in the elderly Australian
war veteran population. Since 2004, the Australian Govern-
ment Department of Veterans’ Affairs (DVA) has funded aquality improvement program, the Veterans’ Medicines
Advice and Therapeutics Education Services (Veterans’
MATES) program [8,9], to bridge the evidence-practice
gap in the provision of health care to Australian war vet-
erans. The overall aim of this paper is to determine
changes in medicine use as a result of the program.
Methods
The Veterans’ MATES program aims to improve medica-
tion use and health outcomes for all persons in the vet-
eran community by delivering interventions to general
practitioners (GPs), pharmacists, and veterans. Social cog-
nitive theory [10,11], the transtheoretical model [12,13],
and the health promotion model Precede-Proceed [14]
were used as the theoretical frameworks that underpinned
the program and were used to predict learning and behav-
iour change (Figure 1). Key features of the implementation
design included the ability to provide routine periodic in-
terventions with ongoing evaluation suitable for participa-
tion by all practitioners (Figure 1). The main intervention
was patient-specific feedback that identified for GPs their
patients with potential medication-related problems. The
feedback included a list of the patient’s relevant medicines,
contained notes identifying the potential problems, and
included tick boxes for GPs to indicate the actions they
would take in response to the information, including the
need for a review of the patient’s therapy (Figure 2).
Supportive educational material was also provided that
included advice to assist the GP in resolving the potential
medication-related problem. In addition, the veterans
identified in the GP mailing were mailed an educational
brochure highlighting potential medication issues related
to the topic and encouraging the veterans to speak with
their doctor. The same educational material was also
provided to all pharmacies and accredited pharmacists
to enable pharmacists to support the practice change
(Figure 2). The program was implemented four times per
year. Mailings were delivered only to those GPs and veterans
who met the criteria for each program and to all pharma-
cies and accredited pharmacists. Between November 2004
and September 2008, 16 educational interventions were
distributed. Twelve of these interventions focused on
changing medication use and are the subject this paper.
The aims of the twelve interventions are listed in Table
one. Four other interventions focused on health service
use, including home medicines review and dose adminis-
tration aids, and are not reported here. For the interven-
tions, material was mailed first to GPs and pharmacists,
with the educational material to veterans provided one
month later to enable GPs to read the material prior to
the veteran visit.
In keeping with health promotion principles involving
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rep resentative 
committee (quarterly). 
Allows stakeholders to 
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Medication related 
problem analysis: 
Conducted quarterly to 
identify topics suitable for
intervention. 
Uses administrative health 
claims data.
Topics must be amenable to 
change by intervention
Problematic in the veteran 
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messages over time are 
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identified by social and 
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and clinical reference group 
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feedback, patient review 
questions, call to action 
questions, organizational 
support and national call 
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Therapeutic Brief (GPs & 
pharmacists): Developed 
by a medical writer, 





Patient specific feedback: 
Prescribing feedback to 
the GP, identifying 
patients who meet the 
criteria for the 
intervention. Includes 
patient review questions 
and response forms with 
call to action questions 
Veteran brochure: 
relevant to the theme of 
the intervention, 
high lights medication 
issues, encourages them 
to speak with their doctor.
Step 1: Social assessmentStep 2: Epidemiological 
assessment
Step 3: Behavioural and  
environmental assessment
Step 4: educational and 
ecological assessment













Step 7: process evaluation Step 8: impact evaluation Step 9: outcome evaluation
Figure 1 Components of veterans’ MATES interventions, linked to steps in the precede-proceed model.
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to stakeholder groups, including health professional and
consumer organizations (Figure 1). The program also
established practitioner and consumer reference groups
which meet twice a year to provide advice on topics, inter-
ventions, and practitioner and consumer needs. The educa-
tional material is developed by a medical writer, supported
by a clinical reference group that meets monthly. Prior to
publication, the material is peer reviewed and also reviewed
by a national representative editorial committee to ensure
both the quality of the material and stakeholder support
for the material and intervention. The program is further
supported by a national call centre staffed by clinical phar-
macists who provide educational support, clarify issues,
ensure problems are quickly identified, and accept com-
plaints. National consultation with stakeholder organiza-
tions and advice from veteran and practitioner reference
groups is ongoing (Figure 1).
Each educational intervention is based on a specific
medicine or health-related topic. To identify topics, the
prevalence of medication-related problems is determined
using DVA administrative health claims data (Figure 1).
In 2004 when the program commenced, there were ap-
proximately 320,000 Australian war veterans, war widows,
or widowers. Their median age was 80 years; over 40
percent regularly used two or more medicines, and 13percent regularly used five or more medicines. With vet-
erans aged 70 years and over dispensed an average of 45
prescriptions per year, the population is at high risk of
medication-related problems because of their high medi-
cation use. DVA health claims data contain details of all
DVA subsidized prescription medicines, medical and al-
lied health services, and hospitalizations for veterans.
Veterans are entitled to receive all medicines subsidized
on Australia’s national pharmaceutical benefits scheme
and entitled to receive additional medicines that are subsi-
dized under the Repatriation Pharmaceutical Benefits
Scheme. DVA maintains a client file, which includes data
on gender, date of birth, date of death, and family status.
Medicines are coded in the data set according to the World
Health Organization (WHO) anatomical and therapeutic
chemical (ATC) classification [15] and the Schedule of
Pharmaceutical Benefits item codes [16]. Hospitalizations
are coded according to the WHO International Classifica-
tion of Diseases [17].
The medication-related problem analyses were gener-
ally based within the therapeutic areas outlined in the
Australian government National Health Priority Areas
(asthma, cardiovascular health, diabetes, mental health,
and arthritis and musculoskeletal conditions) [18]. Criteria
for each topic were that it was problematic in the veteran
community, specific to medication or health service
Figure 2 Intervention materials provided for the veterans’ MATES program.
Roughead et al. BMC Health Services Research 2013, 13:514 Page 4 of 14
http://www.biomedcentral.com/1472-6963/13/514
Roughead et al. BMC Health Services Research 2013, 13:514 Page 5 of 14
http://www.biomedcentral.com/1472-6963/13/514management, amenable to change by the interventions
employed by the Veterans’ MATES program, and able
to be evaluated using DVA administrative data sets. In
addition, the topics chosen were suitable for repeat mes-
sages over time, to increase the persuasiveness of the
messages [19]. In developing the intervention, strategies
consistent with behavioural theories were established.
Every educational intervention included strategies to raise
awareness, improve knowledge, and encourage trial of ap-
propriate behaviours. Each intervention included objectivesTable 1 Educational intervention topics and target audience
Intervention
number and topic
GPs (n) Veterans (n) Pharmacists (n) Aim of educ
Interventions to increase use of medicines
2: Beta-blockers,
take the next step
for heart failure




8573 16612 5459 To increase u
cardiovascula
veterans with
15: Osteoporosis 16876 83110 7967 To increase u
density tests
treatments
















10720 28670 5447 To decrease
7: PPIs in GORD:
Reduce the dose –
keep the benefits















14: COPD 8785 18096 7880 To reduce ne
multiple dev
Interventions with a combination of messages
10: Constipation: a
quality of life issue
for veteran patients
9825 29231 7327 To improve u
constipation
the use of os
and reduce t
13: Clopidogrel 8279 16867 7970 To increase u
aspirin and r
of clopidogre
*Material was not mailed to veterans. For this topic, materials were provided to the
NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; GORD, gato provide useful information to participants; to increase
GPs’ knowledge of the veterans they treat who meet the
target criteria for the intervention; and to change medica-
tion or health service use in line with the messages of the
educational intervention. GPs and pharmacists could
claim professional development points for participating.
This provided an incentive for GPs and pharmacists as
professional development reports are required for main-
taining practicing certificates. Table 1 provides the final
list of interventions and target groups.ational intervention Target criteria for veterans mailed to:
eta-blocker use in
heart failure
Veterans dispensed medicines indicative
of heart failure who were not dispensed




Veterans dispensed medicines indicative of
diabetes (insulin and/or oral
hypoglycaemics)
ptake rates of bone
, and osteoporosis
Women aged 70–79, men aged 80–85 and
those over 50 years admitted to hospital
with a fracture from a same level fall
SAID use in veterans
ilure and diabetes
Veterans with dispensed medicines





use of multiple devices Veterans dispensed inhaled respiratory
medicines
e use of lower-strength
tenance therapy




Veterans 70 years of age or over, dispensed
medicines that should be used with caution





d over 65 years).
Veterans aged >65 years dispensed oral
antipsychotic medicines.
buliser use and reduce
ice use
Veterans dispensed tiotropium or
ipratropium
se of medicines for
; specifically, to increase
motic and bulk laxatives
he use of contact laxatives.
Veterans dispensed laxatives




GPs treating these 6990 patients to pass on to the patient if appropriate.
stro-oesophageal reflux disease; COPD, chronic obstructive pulmonary disease.
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Stakeholder satisfaction was evaluated for all interven-
tions using a one-page reply paid response form that
was mailed with the educational materials. The evalu-
ation forms were designed to minimize additional work-
loads for busy health professionals, thus, the forms were
limited to no more than nine questions (one page) and
all answers required a “tick-box” response only. Evalu-
ation forms were created for every intervention with
questions relevant to the targeted topic. Specific forms
were created for GPs, pharmacists, and veterans. All tar-
geted participants were mailed the evaluation forms. No
follow-up reminders were sent. The response forms in-
cluded questions on the usefulness of the educational
material, as well as likely actions to be taken as a result
of the program. Three months after each intervention,
responses were collated. Individuals could only respond
once for each intervention but could respond to multiple
interventions if they had been targeted in more than one
intervention.Statistical analyses
Segmented regression analysis was used to estimate the
effect of each intervention on medicine utilisation taking
into account the baseline trend prior to the intervention
[20]. A log-binomial generalised estimating equation was
used with an ar (1) error structure to account for correl-
ation between months, clustered by patient. The models
included a constant term, a term for baseline trend prior
to the intervention, an indicator term to estimate the
change in level at the time of the intervention and a
post-intervention trend term to determine the sustain-
ability of the intervention over time. We calculated the
number of people estimated to have changed behaviour
as a result of each intervention based on the number of
veterans targeted at the time of the intervention, the
level change at the time of the intervention plus the
monthly trend change at the time after the intervention
compared to the pre-intervention trend over the
24 month period. The time periods used for the analysis
were as follows: the pre intervention period was the
24 months prior to the month of mail out for each inter-
vention, the intervention period was the four months
immediately following the month of mail out, and the
post-intervention period was the subsequent 20 months
(i.e. month 5 to 24 post mail-out). All analyses were
undertaken using SAS for windows, V9.1.3 SP4 (SAS In-
stitute, Cary, North Carolina, USA).Ethics statement
Ethics approval for the study was obtained from the De-
partment of Veterans’Affairs Human Research Ethics Com-
mittee (reference number: E004/016) and the University ofSouth Australia Human Research Ethics Committee
(reference number: P203/04).Results
The twelve interventions implemented had an average
target group size for each intervention of 33,000 vet-
erans, 10,000 doctors, and 8500 pharmacies/accredited
pharmacists. The target group size and aim of each indi-
vidual intervention is listed in Table 1.
Of the three interventions that aimed to increase medi-
cine use, all achieved statistically significant increases at
the time of the intervention. However, all post-intervention
trends, while remaining positive, were lower than the pre-
intervention trend (Table 2 and Figure 3). Estimated num-
bers of patients with sustained behaviour change over the
subsequent 24 months as a result of the intervention
ranged from 642 to 3234 per intervention.
Of the seven interventions that aimed to reduce use, the
three that targeted one specific medicine to be reduced,
NSAID use in those with heart failure or diabetes, high
dose proton pump inhibitor (PPI) use, and antipsychotic
use in those aged over 65, all achieved significant level
changes at the time of the intervention, ranging from 10%
to 14% (Table 3 and Figure 4). For proton pump inhibitors
and antipsychotics, the impact was increased over the
20 month follow-up period as evidenced by the statisti-
cally significant further reduction in the trends post inter-
vention compared to pre-intervention trends (Table 3).
The estimated number of patients with sustained behav-
iour change over 24 months ranged from 780 to 1725 for
the three interventions. By comparison, the four interven-
tions to reduce use that had multiple messages, medicine
interactions (antidepressant interactions), potentially in-
appropriate medicines in those aged over 70 and re-
spiratory device use did not show significant effects.
Pre-intervention trends, which in most cases were fall-
ing, continued to fall. Duplicate antidepressant use was
the exception, where usage increased despite messages
that duplicate use was not appropriate. The two inter-
ventions that targeted multiple respiratory device use
for those on four or more different devices only reduced
post intervention, but not at the time of the interven-
tion (Table 3).
Table 4 demonstrates the results of two interventions
that had combined messages to increase one aspect of
medicine use and decrease another. Significant changes
were seen in keeping with intervention messages for clo-
pidogrel at the time of the intervention with increased
aspirin use and reduced NSAID use; subsequent trends
remained unchanged. By contrast, laxative use did not
change at the time of the intervention, but subsequent
trends were statistically significant in keeping with inter-
vention messages.
Table 2 Impact of interventions to increase medicine use
Intervention number and topic
(number of veterans targeted)







20 month post intervention trend Estimated number with
changed behaviour from
intervention; sustained over
two years post intervention
2: Beta-blockers, take the next step





7% (p < 0.0001) Trend still increasing but reduced to
0.6% per month (p < 0.0001)
642




1.3% (p < 0.0001) Trend still increasing but reduced to







1.9% (p < 0.0001) Trend still increasing but reduced to






3% (p < 0.0001) Trend still increasing but reduced to
0.1% per month (p < 0. 0.0001)
543




2.8% (p < 0.004) Trend still increasing but reduced to
0.4% per month (p < 0.0001)
712
Increase use in men 4.7% Trend increasing
1.5% per month
8.3% (p < 0.0001) Trend still increasing but reduced to
0.2% per month (p < 0.0001)
2522










































2: Beta blockers, take the next step for heart failure -Rate of use of  
beta blockers by those with heart failure
Pre-intervention period: Mar 2003- Feb 2005. Monthly change: 1.017 (1.015-1.019) p<0.0001. This means that
the number of veterans with CHF using a beta blocker was increasing by 1.7% per month pre-intervention.
Intervention period: Mar 2005 – Jun 2005. Change in use: 1.07 (1.04-1.10) p<0.0001. This means that the  
number of veterans with CHF using beta blockers increased by 7% at the time of the intervention.
Post-intervention period: Jul 2005 – Mar 2007. Monthly change (relative to pre-intervention): 0.989 (0.986- 
0.991) p<0.0001. 
This means that the number of veterans with CHF using beta blockers was decreasing by 1.1% per month
compared to the pre-intervention trend i.e. overall, post-intervention the number of veterans with CHF
dispensed beta blockers increased by 0.6% each mont
Overall effect: 642 additional veterans with CHF were dispensed beta blockers as a result of the intervention
Figure 3 Example of an intervention aiming to increase medicine use.
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a median response rate of 8% (interquartile range 7%-
10%) for GPs, 9% (7%-9%) for pharmacists and 26% (24%-
32%) for veterans. On average, 80% of GPs and 93% of
pharmacists who completed the stakeholder evaluation
found the interventions useful or very useful (Table 5). On
average, 80% of veterans who completed the stakeholder
evaluation found the information provided helpful or very
helpful (Table 5).
Discussion
In our study, all educational interventions aiming to in-
crease medicine use were effective, with relative effect
sizes ranging from 1% to 8% at the time of the interven-
tion. However, all of the interventions also had a statisti-
cally significant effect on the post-intervention trend
which was reduced compared to the pre-intervention
trend. The reduced trend observed after the intervention
could be due to the reduced naïve patient pool which re-
sults as a direct consequence of the immediate impact of
the intervention. It also suggests that the effect of inter-
ventions to increase use of medicines may not be sus-
tained and would require repeat messages over time to
be sustained.
Educational interventions aiming to reduce unnecessary
use of medicines had mixed results. Those with very specific
messages (reduce use of non-steroidal anti-inflammatoryagents in high risk patients; reduce use of high dose proton
pump inhibitors; and reduce use of risperidone for the be-
havioural and psychological symptoms of dementia) were
all effective, with relative effect sizes up to 14%. Educa-
tional interventions with more generic adverse event mes-
sages (avoid antidepressant interactions, reduce potentially
inappropriate medicine use in the elderly) had no measur-
able effect on practice. Interventions less clearly linked to
patient harm or poor health outcomes and with combina-
tions of messages, such as those to reduce use of multiple
inhaler devices, and improve the use of medicines for con-
stipation were associated with practice change in some
but not all aspects of care and were often found to be sta-
tistically significant in the post-intervention trend only,
not at the time of the intervention. It is likely that the
combination of messages meant these interventions were
less effective. The evaluation of these interventions may
also have been confounded by patient practice, where
these medicines may be used “as required” and thus
change in dispensing quantities may be delayed, hence the
positive effect in the post-intervention trend only.
The relative effect of our results, which ranged between
1% and 14%, is consistent with the median relative effect
reported in the Cochrane review of audit and feedback of
8%7. Our results suggest well implemented, behaviourally
grounded, ongoing programs do achieve similar results to
randomised control results.
Table 3 Impact of interventions to reduce use
Intervention number and topic
(number of veterans targeted)















4: Clinical risk management:
NSAIDs (n = 9885)
Reduce NSAID use in
those with heart failure
15.6% Trend decreasing −
0.8% per month
−11.4% (p < 0.0001) Trend still decreasing
(non-significant to prior) − 0.7%
per month (p = 0.87)
1163 (680 heart failure patients
and 483 diabetes patients)
Reduce NSAID use in
those with diabetes
17.9% Trend decreasing −
1.2% per month
−10.2% (p < 0.0001) Trend still decreasing but
reduced to − 0.3% per
month p = 0.006
5: Antidepressants: three




3.5% Trend increasing 0.2%
per month
0.6% p = 0.72 Trend increasing at a rate of




5.8% Trend decreasing −
0.6% per month
−1.0% p = 0.64 Trend still decreasing
(non-significant to prior) − 0.8%
per month p = 0.23
6: Inhaled respiratory medicines:
optimising use (n = 28670)
Reduce multiple device
use (3 different devices)
9.5% Trend increasing 0.2%
per month
−0.11% p = 0.32 Trend now decreasing
(non-significant to prior) − 0.2%
per month p = 0.23
100 patients no longer on
4 or more different devices
Reduce multiple device use
(4 or more different devices)
2% Trend increasing 0.1%
per month
2% p = 0.60 Trend now decreasing − 0.6%
per month p = 0.01
7: PPIs in GORD: Reduce the
dose – keep the benefits
(n = 62460)
Reduce use of high dose
proton pump inhibitors
(measured as increase in
low-dose use)
2.5% Trend of low dose
increasing 0.6% per
month
14.5% (p < 0.0001)
Increase in low dose
use
Trend of low dose increasing at
greater rate 0.9% per month
(p = 0.007)
780
8: Reducing adverse drug
events for your veteran
patients (n = 32484)
Reduce use of potentially
inappropriate medicines
14.7% Trend decreasing −
0.2% per month
−0.3% p = 0.12 Trend still decreasing
(non-significant to prior) − 0.2%
per month p = 0.63
No effect
12: Antipsychotics in
dementia (n = 6690)
Reduce antipsychotic use 0.54% Trend increasing 3.6%
per month
−14.3% (p < 0.0001) Trend increasing but at a reduced
rate 0.8% per month (p < 0.0001)
1725
14: COPD (n = 18096) Reduce multiple device
use (4 or more different
devices)
2% Trend increasing 0.1%
per month
2% p = 0.68 Trend now decreasing − 1.1%
per month p <0.0001
105 patients no longer on
4 or more different devices
Reduce use of nebules 15.2% Trend decreasing −
0.6% per month
2% p = 0.07 Trend decreasing (non-significant
to prior)− 0.8% per month p = 0.2




















































































































12: Antipsychotics in dementia -
Rate of use of risperidone
Pre-intervention period: Oct 2005-Sep 2007. Monthly change: 1.036 (1.03-1.04); p<0.0001. This
means that use of risperidone was increasing by 3.6% per month pre-intervention.
Intervention period: Oct 2007-Jan 2008. Change in use: 0.86 (0.82-0.89); p<0.0001. This means
that use of risperidone decreased by 14.3% at the time of the intervention.
Post-intervention period: Feb 2008-Sep 2009. Monthly change (relative to pre-intervention): 0.97
(0.96-0.98); p<0.0001. This means that the rate of use was decreasing by 2.7% per month relative
to the pre intervention trend.
i.e. overall use continued to increase, but only by 0.9% per month. Overall effect: 1725 fewer
veterans dispensed risperidone.
Figure 4 Example of an intervention aiming to reduce medicine use.
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targeting all general practitioners in Australia. Thus, the
program requires sustained engagement of participants
to maintain its success. The outcomes reported here
demonstrate a bridging of existing evidence-practice
gaps in diverse therapeutic areas. The behavioural inter-
vention, utilising patient-specific prescriber feedback, is
based on evidence from randomised controlled trials [7].
The implementation and evaluation frameworks were
based on behavioural theories and have enabled imple-
mentation of evidence in practice. The significance of this
work lies in its ability to bridge the research-practice
gap with an implementation and evaluation framework
that enables sustained engagement and demonstration
of effectiveness.
The changes in medication use reported in this paper
are associated with improvements in health outcomes.
We have previously shown that PPI use in the Australian
veteran population was associated with increased use of
antibiotics (RR 1.23, 95% CI 1.21–1.24) and increased
risk of hospitalisation for pneumonia (RR 1.16, 95% CI
1.11–1.22) [21]. We have demonstrated increased risk of
hospitalisation associated with use of NSAIDs amongst
veterans with diabetes (IRR 1.31, 95% CI 1.08 – 1.60)
and veterans dispensed medicines indicative of heart fail-
ure (IRR 1.34, 95% CI 1.13 – 1.58) [22]. We have also
demonstrated increased risk of death, stroke, hip frac-
ture and pneumonia with antipsychotic use in the elderlyveteran population [23-25]. We also demonstrated that
beta-blocker use was associated with less hospitalisations
for heart failure in elderly veterans [26]. The Veterans’
MATES program was associated with declines in use of
proton pump inhibitors, reducing NSAID use, reducing
antipsychotic use and increasing beta-blocker use in
those with heart failure, all suggesting health outcomes
for veterans have improved.
The implementation of the Veterans’ MATES program
includes all the elements identified within the National
Institute for Clinical Excellence Principles of Best Practice
for Clinical Audit [27] and is consistent with the behav-
ioural theories, particularly the Precede-Proceed Model of
Health Promotion [28] and Social Cognitive Theory [11]
which identify the need for developing supportive envi-
ronments, raising awareness, developing knowledge and
skills, encouraging cognitive processing of the information
and reinforcing messages over time. Creating an environ-
ment conducive to change is achieved via stakeholder sup-
port and involvement, which is an ongoing component of
the program, achieved through twice yearly meetings of
the practitioner and veteran reference groups, quarterly
meetings with the national representative steering com-
mittee and regular attendance at health professional meet-
ings. Face-to face meetings are called as required with
national bodies for selected topics. Topic selection is al-
ways based on an identified medication-related problem,
where data analysis has revealed a problem which is
Table 4 Interventions with combination messages (to reduce and increase medicines use)
Intervention number
and topic (number of
veterans targeted)






Intervention effect (%) 20 month post
intervention trend
Estimated number with changed
behaviour as a result of intervention;
sustained over two years
post intervention
10: Constipation: a quality
of life issue for veteran





1.8% (p = 0.11) Trend increasing at greater
rate 1.2% per month (p = 0.002)
2047 (825 additional people on
osmotic laxatives, 410 additional
people on contact laxatives and




3.0% (p = 0.0007) Trend still increasing (non-significant
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0.8% (p = 0.34) Trend now decreasing at greater








3.0% (p = 0.018) Trend still increasing (non-significant
to prior) 0.7% per month (p = 0.4)
1114 (825 now on aspirin with






− 0.3% per month
−5.3% (p = 0.002) Trend still increasing (non-significant




















Table 5 Stakeholder evaluation: stakeholders who found the information “useful or very useful” (GPs and pharmacists)
or “helpful or very helpful” (veterans)
Intervention number and topic GP feedback:
useful or very useful#
Pharmacist feedback:
useful or very useful#
Veteran feedback:
helpful or very helpful#
2: Beta-blockers, take the next step for heart failure 69% N/A* 81%
3: Diabetes triple check 71% 92% 82%
4: Clinical risk management: NSAIDs 73% 95% 80%
5: Antidepressants: three steps towards safer use 81% 92% 81%
6: Inhaled respiratory medicines: optimising use 80% 91% 86%
7: PPIs in GORD: Reduce the dose – keep the benefits 81% 95% 72%
8: Reducing adverse drug events for your veteran patients 84% 95% 86%
10: Constipation: a quality of life issue for veteran patients 84% 92% 72%
12: Antipsychotics in dementia 85% 93% N/A*
13: Clopidogrel 86% 98% 87%
14: COPD 79% 90% 77%
15: Osteoporosis 84% 92% 77%
Average 80% 93% 80%
#Percent of GPs, veterans or pharmacists who provided feedback.
*No feedback was sought from pharmacists for intervention 2 or from veterans for intervention 12.
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has the support of the clinical reference group and stake-
holders. Problems which are not measureable in the data
are not implemented under this program. An intervention
plan is developed which includes clear objectives, the
strategies to meet each objective and process impact and
outcome indicators for evaluation. This plan is endorsed
by all groups for each intervention. The material includes
call to action questions to promote cognitive processing.
Stakeholder feedback through our reference groups, call
centre, e-mail comments line and one-page response
forms identify both barriers and enablers to continue to
improve the program. The evaluation results are routinely
fed-back to all reference groups and inform the ongoing
interventions. Further, the ongoing nature of the program
enables repeat messages over time.
While it could be argued that programs such as this
should be evaluated using more rigorous methods, such
as randomized controlled designs, we advocate that this
program represents true implementation science. Previ-
ous randomized controlled trial data have demonstrated
the efficacy of audit and feedback. Similarly, randomized
controlled trial data were available for all Veterans’
MATES interventions targeting medicine efficacy and ei-
ther randomised controlled trial or well conducted ob-
servational evidence is available for all medicine safety
issues targeted. For this reason, this program sought to
implement the evidence, and as a consequence used
health program evaluation methods for the analysis. For
this reason, we are limited to methods of evaluation
such as time series or non-equivalent groups. As thisprogram was a national program, for the majority of in-
terventions no comparison group was able to be se-
lected, thus time-series was the method used. A further
challenge in evaluating ongoing programs are the occur-
rence of simultaneous interventions, or interventions
immediately prior or after which may impact on the eva-
lution and lead to over-estimates or under-estimates of
results. This may occur due to changes in co-payments,
product withdrawals, changes to subsidy and changes in
safety or efficacy or indications. While at times these en-
vironmental changes may obscure intervention effects,
well targeted programs can take advantage of these op-
portunities to enhance intervention effect, for example
by reinforcing safety messages and giving clear advice on
what to use instead. The consistency of our results, in
terms of relative effect size, across a range of topics and
the consistency of that effect with existing studies using
controlled designs [7] suggests our evaluation is likely to
be estimating true effect.
We have demonstrated that a well designed program
using proven techniques from implementation research,
designed with local characteristics in mind and in consult-
ation with key stakeholders can be effective. The Australian
medicines and health environment has been exposed to
a formal National Medicines Policy for a decade [29].
This policy initiative has funded national quality use of
medicines programs, for example the National Prescribing
Service, which has been in operation for about 10 years.
While this environment may predispose both health prac-
titioners and consumers to be favourable to the types of
interventions implemented by the Veterans’ MATES
Roughead et al. BMC Health Services Research 2013, 13:514 Page 13 of 14
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over-and-above those that have been achieved through
these other policy initiatives [30-32].
Conclusions
The Veterans’ MATES program has been successful in
achieving positive, significant changes in medicines and
health service use over time. Educational interventions
with a clear, single message tended to be most successful
in changing practice as were those which aimed to in-
crease use. The Veterans’ MATES program provides a
model that could be replicated in other settings such as
a national health service or a health insurance organisa-
tion where bridging the evidence-practice gap is proving
a significant challenge.
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